Are ampicillin or ceftazidime (Ceftazidime) effective against Staphylococcus aureus in treating bullous impetigo?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Neither Ampicillin Nor Ceftazidime Provide Adequate Coverage for Bullous Impetigo

Neither ampicillin nor ceftazidime should be used to treat bullous impetigo, as both agents lack reliable activity against Staphylococcus aureus, which is the exclusive causative pathogen of this condition. 1, 2

Why These Agents Are Inappropriate

Ampicillin's Critical Gap in Coverage

  • Ampicillin is completely ineffective against penicillinase-producing staphylococci, which constitute the vast majority of S. aureus isolates causing impetigo 3
  • The FDA label explicitly states that ampicillin "is inactivated by penicillinase and therefore is ineffective against penicillinase-producing organisms including certain strains of staphylococci" 3
  • Bullous impetigo is caused exclusively by toxin-producing S. aureus, making ampicillin an inappropriate choice 1, 2

Ceftazidime's Spectrum Mismatch

  • Ceftazidime is a third-generation cephalosporin designed primarily for gram-negative coverage, particularly Pseudomonas aeruginosa, and has poor activity against gram-positive organisms like S. aureus 4
  • While the FDA label lists S. aureus in its spectrum, ceftazidime was explicitly excluded from WHO guidelines for skin infections because it is "suitable for targeted treatment but not empiric treatment" of staphylococcal infections 5
  • The drug's design prioritizes gram-negative pathogens over the gram-positive cocci that cause impetigo 4

Recommended First-Line Alternatives

For Presumed Methicillin-Susceptible S. aureus (MSSA)

  • Cephalexin 25-50 mg/kg/day divided into 4 doses for 7 days is the first-line oral antibiotic recommended by the American Academy of Pediatrics and IDSA 5, 1
  • Dicloxacillin at the same dosing is an equally effective alternative 5, 1
  • Both agents are penicillinase-stable and provide reliable anti-staphylococcal coverage 6

When MRSA is Suspected or Confirmed

  • Clindamycin 20-30 mg/kg/day divided into 3 doses for 7 days provides excellent coverage 5, 1
  • Sulfamethoxazole-trimethoprim (SMX-TMP) 8-12 mg/kg/day divided into 2 doses for 7 days is another effective option 5, 1
  • Doxycycline 2-4 mg/kg/day divided into 2 doses for 7 days can be used in children over 8 years old 5, 1

Critical Clinical Considerations

Pathogen-Specific Treatment

  • Bullous impetigo is caused exclusively by S. aureus, unlike non-bullous impetigo which may involve Streptococcus pyogenes 1, 2
  • Studies demonstrate that S. aureus is isolated in 100% of bullous impetigo cases and in 62-81% of all impetigo cases overall 7, 6
  • This makes anti-staphylococcal coverage absolutely essential 2, 7

Common Pitfall to Avoid

  • Do not use penicillin V or ampicillin for impetigo treatment, as clinical trials show treatment failure rates of 24% with penicillin V compared to 0-4% with appropriate anti-staphylococcal agents 6
  • The historical use of penicillin for impetigo is outdated and no longer appropriate given current pathogen profiles 8, 6

Resistance Considerations

  • In areas with high MRSA prevalence, empiric therapy should cover MRSA until culture results are available 1
  • Erythromycin resistance exceeds 20% in many regions, making macrolides less reliable 7
  • All S. aureus isolates remain sensitive to flucloxacillin and cephalosporins like cephalexin 7

References

Guideline

Impetigo Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Impetigo: diagnosis and treatment.

American family physician, 2014

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

[Contagious impetigo--pathogen spectrum and therapeutic consequences].

Deutsche medizinische Wochenschrift (1946), 2000

Research

Diagnosis and treatment of impetigo.

American family physician, 2007

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.